Another group consists of LAMB2, XRCC6, MEF2C, RBM5, FOXP1, NUDCP2, LGALS3, TMEM185A, and C1S, which was down-regulated in most patients with stage III serous ovarian cancer (Figure 4 and Table 3). This evidence concerns the gene XRCC6 and ovarian serous adenocarcinoma.